DPDaily Peptide

THYMOSIN Α-1 · DECODED

← Back to Decoded
35+ COUNTRIES APPROVEDNOT FDA APPROVEDIMMUNE MODULATOR

Thymosin α-1

Decoded · International Approval · Not FDA Approved

Approved in 35 countries. Not the US. Different evidence standards, different outcomes. Thymosin α-1 has documented international clinical use across more countries than almost any other compound in this list — approved for hepatitis B, cancer treatment adjuvant, and immune deficiency indications in dozens of countries. The FDA requires Phase 3 evidence meeting its specific trial standards. The TESTS trial — the largest conducted under Western GCP standards — did not meet its primary endpoint. Both data sets are part of the picture.

BY THE NUMBERS

28
AMINO ACIDS · ACETYLATED N-TERMINUS
35+
COUNTRIES WITH REGULATORY APPROVAL (ZADAXIN)
1,106
PARTICIPANTS IN TESTS TRIAL (BMJ 2025)
0
FDA APPROVALS FOR ANY INDICATION

HOW IT WORKS

A 28-amino-acid endogenous peptide produced by the thymus. Acts as a Toll-like receptor agonist (primarily TLR-9), activating dendritic cells and promoting CD4+ T-helper cell differentiation, enhancing both innate and adaptive immune response. This mechanism is the basis for its international approval as Zadaxin for hepatitis B, hepatitis C, and as a cancer immunotherapy adjuvant.

WHERE IT CAME FROM

Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino acid peptide produced by the thymus gland. The thymus is an immune organ located behind the sternum that is critical to the maturation of T-cells, the lymphocytes responsible for coordinating adaptive immune responses. Tα1 was first isolated from thymosin fraction 5 by Allan Goldstein and colleagues in the 1970s and is one of the thymic peptides responsible for T-cell maturation and immune system development.

The synthetic version, sold under the brand name Zadaxin (manufactured by SciClone Pharmaceuticals), has been approved in more than 35 countries for indications including chronic hepatitis B, hepatitis C adjuvant therapy, cancer immunotherapy support, and primary immunodeficiency. Its mechanism involves stimulation of T-helper cells, natural killer cells, and dendritic cells, essentially amplifying the immune system's ability to identify and respond to pathogens and abnormal cells. Despite this international track record, Zadaxin has never received FDA approval in the United States, and the largest Phase 3 trial ever conducted, the TESTS trial published in BMJ in 2025, did not meet its primary endpoint in the general sepsis population.

THE STUDIES

Historical
Chronic Hepatitis B: International Approval Basis: Multiple trials conducted primarily in Asia established Thymosin α-1 as an effective adjuvant treatment for chronic hepatitis B, a viral liver disease affecting hundreds of millions of people globally. The trials showed that Tα1 improved immune clearance of the hepatitis B virus, particularly in combination with antiviral agents. This body of work led to regulatory approvals in China and other Asian countries where hepatitis B prevalence is high. These trials used different regulatory and methodological standards than FDA Phase 3 requirements, which is part of why US approval was not pursued successfully.
2025
TESTS Trial (BMJ): Phase 3 Sepsis: The TESTS trial (Thymosin Alpha-1 for Sepsis) is the largest and most methodologically rigorous study ever conducted on Thymosin α-1. It enrolled 1,106 patients with sepsis, a life-threatening immune response to infection that kills approximately 270,000 Americans annually. The primary endpoint, 28-day mortality, was not met for the general sepsis population. Subgroup analyses suggested possible benefit in patients with specific immune phenotypes, but subgroup findings require independent confirmation before clinical decisions can be based on them. The TESTS trial is an honest negative result for the general sepsis indication and should be read as such.
2020–2022
COVID-19 Adjuvant Studies: During the COVID-19 pandemic, Thymosin α-1 was evaluated in several trials as an immune adjuvant, particularly in China and Italy. Results were mixed. Some studies in severely ill patients showed improved outcomes; others did not. These studies were conducted under emergency conditions with heterogeneous patient populations and variable methodology. They are consistent with Tα1's mechanism but do not establish it as a standard of care for COVID-19.

WHAT THE STUDIES SHOW

ESTABLISHED (INTERNATIONAL)

  • ▸T-cell maturation and activation (confirmed mechanism)
  • ▸Hepatitis B viral clearance improvement in adjuvant trials
  • ▸NK cell and dendritic cell stimulation
  • ▸Approved in 35+ countries for hepatitis B and immune deficiency

MIXED / PENDING

  • ▸Sepsis mortality: TESTS trial primary endpoint NOT met
  • ▸COVID-19 adjuvant: inconsistent results across studies
  • ▸Cancer immunotherapy support: promising but not conclusive in Western trials
  • ▸Subgroup benefits in TESTS: possible, unconfirmed

US EVIDENCE GAP

  • ▸No FDA approval for any indication
  • ▸Western Phase 3 trials have not consistently confirmed international data
  • ▸TESTS trial used highest rigor standard: failed primary endpoint
  • ▸Regulatory gap between international approval and FDA requirement is real and significant

SIDE EFFECTS

COMMON (FROM APPROVED USE)

  • ▸Injection site reactions
  • ▸Mild flu-like symptoms (consistent with immune activation)
  • ▸Fatigue
  • ▸Safety profile is well-established across decades of international clinical use

NOTABLE / MONITOR FOR

  • ▸Immune activation in autoimmune conditions: theoretical concern with immune-stimulating compounds
  • ▸Not approved in the US: must be compounded or sourced from international suppliers
  • ▸Quality varies significantly between compounding sources
  • ▸Grey market injectable: purity and concentration unverified outside regulated manufacturing

REGULATORY STATUS

FDA STATUS
Not FDA approved · International approval only (Zadaxin)
PHASE
Approved internationally · TESTS Phase 3 negative in sepsis
PROJECTED NDA
No active US NDA · SciClone has not pursued FDA approval path

Thymosin α-1 is sold internationally as Zadaxin by SciClone Pharmaceuticals, a cGMP-manufactured pharmaceutical with regulatory approval in 35+ countries for chronic hepatitis B, chronic hepatitis C, and cancer adjuvant therapy. It has never received FDA approval and no active US NDA has been filed. Its US 503A compounding history is distinct from the April 2026 12-compound batch: the FDA placed Thymosin α-1 in Category 2 in September 2023, then removed it from Category 2 in September 2024 after nominators withdrew their nominations. The PCAC reviewed it on December 4, 2024; a final determination was still pending as of June 2026. This means US compounding eligibility is legally unsettled: not authorized, not prohibited. The TESTS trial (BMJ 2025) was a significant negative result for the sepsis indication specifically and should be understood as such. It does not negate decades of international prescribing data for its approved indications.

PROS & CONS

PROS

  • +Legitimate international approval history (35+ countries, Zadaxin brand)
  • +Mechanism is well-characterized: T-cell maturation, NK cell activation
  • +Decades of clinical use data provides a safety profile most grey market compounds lack
  • +Proven in hepatitis B adjuvant therapy with multiple supporting trials
  • +Not a WADA-prohibited substance

CONS

  • −FDA has not approved it for any indication
  • −TESTS trial (Phase 3, n=1,106) did not meet primary endpoint in general sepsis
  • −International approval standards differ from FDA Phase 3 requirements
  • −Not on 503A approved compounding list in the US
  • −Grey market US supply: compounding quality varies
  • −Western Phase 3 evidence has not been convincingly positive

DAILY PEPTIDE VERDICT

RANKING

Internationally Credible, Domestically Unproven

Thymosin α-1 has the most extensively documented clinical track record of any compound in the immune category in this series. Thirty-five countries don't approve something based on nothing. The hepatitis B data is real. The mechanism is established. The problem is that when the highest-quality Western trial (TESTS, n=1,106, Phase 3) ran in sepsis, it did not meet its primary endpoint. That's a meaningful negative result, not something to dismiss. The compound is not unsafe. For the US market, the FDA has not approved Thymosin α-1 for any indication, and the largest Phase 3 trial conducted under Western GCP standards did not meet its primary endpoint. The international data and the FDA data tell different stories. Both are part of the picture.

Also in IMMUNE

// IMMUNE

KPV

GREY MARKETPRECLINICAL

// IMMUNE

LL-37

GREY MARKETPHASE 1

DISCLAIMER · EDUCATIONAL USE ONLY

This document is for educational and informational purposes only. Thymosin α-1 does not hold general FDA approval for human use. Information here synthesizes publicly available research data and does not constitute medical advice.